Mar 28, 2025 · CD79B (CD79b Molecule) is a Protein Coding gene. Diseases associated with CD79B include Agammaglobulinemia 6, Autosomal Recessive and Agammaglobulinemia 6. Among its related pathways are Autodegradation of the E3 …

In this review, the authors discuss the molecular biology of CD79 and the frequency and usefulness of CD79 expression in these neoplasms. CD79 is composed of CD79a and CD79b components expressed almost exclusively on B cells and B-cell neoplasms.

Dec 14, 2021 · Polatuzumab vedotin is an antibody–drug conjugate targeting CD79b, which is ubiquitously expressed on the surface of malignant B cells.

CD79B is a subunit of the heterodimer B-cell receptor Igα/Igβ (CD79A/CD79B). You might find these chapters and articles relevant to this topic. Michele Bibas, in Reference Module in Biomedical Sciences, 2024. One component of the B-cell receptor (BCR) signaling pathway comprises CD79A and CD79B.

Nov 15, 2022 · We explored the mechanism for IgM surface expression by CRISPR/Cas9-induced deletion of CD79A or CD79B in four B lymphoma cell lines. Deletion of either CD79 protein caused loss of surface IgM in all cell lines and reduced fitness in three.

Igα (CD79a)/Igβ (CD79b) are essential components of BCR that are indispensable for its functionality, signal initiation, and signal transduction. CD79a/CD79b-mediated BCR signaling is required for the survival of normal as well as malignant B cells via a wide signaling network.

Our study highlights that CD79A and CD79B are required for surface IgM expression in human B cells and illuminates the importance of IgM expression level for signaling and fitness. The development and function of B cells depend on signals from the B-cell receptor (BCR).

Nov 2, 2023 · Introduction: CD79B is a target of polatuzumab vedotin, an antibody-drug conjugate, which significantly improved the prognosis of both previously untreated and relapsed/refractory patients with diffuse large B-cell lymphoma (DLBCL).

Feb 8, 2025 · CD79B overexpression leading to activation of AKT/MAPK is a potential mechanism underlying primary ibrutinib resistance in ABC-DLBCL, and support its utility as an effective biomarker to predict therapeutic response to ibrutinib.

Feb 8, 2025 · Title: CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma. Prevalence and prognostic value of MYD88 and CD79B mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.